NeurAxis (NASDAQ:NRXS) CFO Buys $14,882.28 in Stock

NeurAxis, Inc. (NASDAQ:NRXS) CFO Timothy Robert Henrichs bought 7,593 shares of the firm’s stock in a transaction that occurred on Wednesday, April 1st. The stock was bought at an average price of $1.96 per share, with a total value of $14,882.28. Following the transaction, the chief financial officer directly owned 7,593 shares in the company, valued at $14,882.28. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

NeurAxis Stock Performance

NeurAxis stock opened at $7.25 on Monday. NeurAxis, Inc. has a 52 week low of $1.33 and a 52 week high of $7.97. The stock has a market cap of $81.11 million, a price-to-earnings ratio of -3.94 and a beta of 1.89. The company’s 50-day moving average price is $5.80 and its two-hundred day moving average price is $4.17.

Wall Street Analysts Forecast Growth

Separately, Craig Hallum raised their price objective on shares of NeurAxis from $8.00 to $13.00 and gave the company a “buy” rating in a research note on Friday, March 20th. One research analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $13.00.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of NRXS. Money Concepts Capital Corp acquired a new position in NeurAxis during the third quarter worth about $103,000. Citadel Advisors LLC lifted its holdings in NeurAxis by 39.6% in the 3rd quarter. Citadel Advisors LLC now owns 35,627 shares of the company’s stock valued at $110,000 after acquiring an additional 10,103 shares during the last quarter. Manatuck Hill Partners LLC acquired a new stake in NeurAxis in the 2nd quarter valued at about $122,000. State Street Corp bought a new position in shares of NeurAxis during the 4th quarter valued at about $139,000. Finally, Geode Capital Management LLC grew its stake in shares of NeurAxis by 48.8% in the 4th quarter. Geode Capital Management LLC now owns 75,653 shares of the company’s stock worth $343,000 after purchasing an additional 24,817 shares during the last quarter. Institutional investors own 11.77% of the company’s stock.

About NeurAxis

NeurAxis (NASDAQ: NRXS) is a clinical-stage biotechnology company focused on the discovery and development of therapeutic candidates for diseases of the central nervous system. The company leverages a proprietary approach to deliver small molecules and biologics across the blood–brain barrier, aiming to address conditions ranging from acute neural injury to chronic neurodegenerative disorders.

NeurAxis advances its pipeline through a combination of in-house research, external collaborations with academic medical centers and contract research organizations, and strategic licensing agreements.